FIELD: medicine, pharmaceutics.
SUBSTANCE: present group of inventions refers to medicine, namely to a combined therapy consisting of a dipeptidyl peptidase 4 (DPP4) inhibitor and a sodium glucose co-transporter (SGLT) inhibitor. The combined administration of the DPP4 and SGLT inhibitors of specific chemical structure provides higher blood plasma glucagon-like peptide-1 (GLP-1) due to their synergetic effect.
EFFECT: effect can be used for the effective treatment of diabetes and other diseases and conditions the pathogenesis of which is characterised by an importance of the GLP-1 levels.
15 cl, 6 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DEUTERATED BENZYL BENZENE DERIVATES AND METHODS FOR USE | 2009 |
|
RU2509773C2 |
| USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | 2010 |
|
RU2600869C2 |
| MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
| COMBINATION, INCLUDING A) PYRIMIDYLAMINOBENZAMIDE AND B) KINASE Thr315lle INHIBITOR | 2007 |
|
RU2481840C2 |
| TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | 2011 |
|
RU2661410C2 |
| HDAC INHIBITORS | 2014 |
|
RU2665554C2 |
| METHOD FOR TREATMENT OF STATES CAUSED BY p38 KINASES AND PYRROLOTRIAZINE COMPOUNDS USED AS KINASE INHIBITORS | 2001 |
|
RU2316556C2 |
| NEW INHIBITORS OF 17 β-HYDROXYSTEROID-DEHYDROGENASE TYPE I | 2004 |
|
RU2369614C2 |
| ENPP1 INHIBITORS AND METHODS OF MODULATING THE IMMUNE RESPONSE | 2018 |
|
RU2800798C2 |
| TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | 2013 |
|
RU2665134C2 |
